10x Genomics is trading at $43.35 (-4.93%) after August 6, 2026 release triggered a negative after-hours reaction despite revenue and adjusted-loss beats; investors focused on Atera’s transition and near-term outlook.
- Q2 revenue reached $151.04 million, above the $146.64 million estimate; adjusted loss was $0.14 per share versus $0.24 forecast.
- Full-year revenue guidance rose to $610 million-$630 million, although revenue declined year over year.
- Shares closed August 6 at $45.60, down 3.92%, before additional extended-hours selling.